Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A fixed-dose combination drug containing **drotaverine**, an antispasmodic agent (phosphodiesterase 4 inhibitor), and **ibuprofen**, a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and anti-inflammatory action. The combination is formulated to provide both relief from smooth muscle spasms and pain, particularly effective in conditions such as menstrual cramps (dysmenorrhea) and abdominal spasms. Drotaverine acts by selectively inhibiting phosphodiesterase 4 (PDE4), relaxing smooth muscle without anticholinergic effects, while ibuprofen inhibits cyclooxygenase (COX) enzymes to decrease prostaglandin synthesis, reducing inflammation and pain[1][3][4]. The combination may be available as a monolithic or bilayer tablet developed for improved patient compliance and enhanced efficacy in pain management[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on drotaverine + ibuprofen.